President and CEO Kurdikar Devdatt bought $140,937 worth of shares (30,000 units at $4.70), increasing direct ownership by 4% to 804,919 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
- SVP and CFO Elguicze Jacob bought $93,360 worth of shares (20,000 units at $4.67), increasing direct ownership by 7% to 309,139 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
- Director Hombach Robert J. bought $223,848 worth of shares (45,000 units at $4.97), increasing direct ownership by 70% to 109,587 units (SEC Form 4)
4 - Embecta Corp. (0001872789) (Issuer)
- Core Labs upgraded by Johnson Rice with a new price target
Johnson Rice upgraded Core Labs from Hold to Buy and set a new price target of $21.00
- Korea Electric Power Corp downgraded by Nomura
Nomura downgraded Korea Electric Power Corp from Buy to Neutral
- Bio-Techne downgraded by Wells Fargo with a new price target
Wells Fargo downgraded Bio-Techne from Overweight to Equal Weight and set a new price target of $73.00
- Large owner Lynx1 Capital Management Lp bought $78,809 worth of shares (6,684 units at $11.79) (SEC Form 4)
4 - Korro Bio, Inc. (0001703647) (Issuer)
- Accelerant Holdings downgraded by William Blair
William Blair downgraded Accelerant Holdings from Outperform to Mkt Perform
- Lake Street initiated coverage on RF Industries with a new price target
Lake Street initiated coverage of RF Industries with a rating of Buy and set a new price target of $19.00
- Goldman initiated coverage on Vail Resorts with a new price target
Goldman initiated coverage of Vail Resorts with a rating of Sell and set a new price target of $132.00
- Analyst resumed coverage on Salesforce with a new price target
Analyst resumed coverage of Salesforce with a rating of Overweight and set a new price target of $250.00
- Raymond James initiated coverage on Polaryx Therapeutics with a new price target
Raymond James initiated coverage of Polaryx Therapeutics with a rating of Strong Buy and set a new price target of $6.00
- The Benchmark Company resumed coverage on MACOM Tech with a new price target
The Benchmark Company resumed coverage of MACOM Tech with a rating of Buy and set a new price target of $375.00
- Canaccord Genuity initiated coverage on Kazia Therapeutics with a new price target
Canaccord Genuity initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $29.00
- The Benchmark Company initiated coverage on Allegro Microsystems with a new price target
The Benchmark Company initiated coverage of Allegro Microsystems with a rating of Buy and set a new price target of $60.00
- Morgan Stanley initiated coverage on Achieve Life Sciences with a new price target
Morgan Stanley initiated coverage of Achieve Life Sciences with a rating of Overweight and set a new price target of $13.00
- Tronox downgraded by Analyst with a new price target
Analyst downgraded Tronox from Neutral to Underweight and set a new price target of $5.00
- StubHub Holdings downgraded by BofA Securities with a new price target
BofA Securities downgraded StubHub Holdings from Neutral to Underperform and set a new price target of $7.50
- Stryker downgraded by Wolfe Research
Wolfe Research downgraded Stryker from Outperform to Peer Perform